Novo Nordisk A/S - share repurchase programme
Rhea-AI Summary
Novo Nordisk (NYSE:NVO) is executing a share repurchase programme under EU Safe Harbour rules as part of an overall plan to buy back up to DKK 15 billion of B shares over 12 months starting 4 February 2026.
Under the sub-programme initiated on 6 May 2026, the company may repurchase B shares for up to DKK 11.2 billion through 1 February 2027. From 20–24 July 2026, Novo Nordisk repurchased 960,000 B shares, bringing accumulated purchases under this sub-programme to 11,160,000 shares for DKK 3,362,368,903. As of 24 July 2026, a total of 25,919,179 B shares have been repurchased since 4 February 2026 for DKK 7,162,368,893 at an average price of DKK 276.33. The company now holds 43,104,480 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Positive
- DKK 15 billion 12‑month B share repurchase programme from 4 February 2026
- Repurchased 25,919,179 B shares since 4 February 2026 for DKK 7,162,368,893
- Treasury position at 43,104,480 B shares, equal to 1.0% of share capital
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 20 July 2026, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 10,200,000 | 3,053,177,399 | |
| 20 July 2026 | 195,000 | 329.69 | 64,289,125 |
| 21 July 2026 | 190,000 | 324.17 | 61,591,795 |
| 22 July 2026 | 190,000 | 321.63 | 61,108,864 |
| 23 July 2026 | 190,000 | 313.46 | 59,557,220 |
| 24 July 2026 | 195,000 | 321.25 | 62,644,500 |
| Accumulated under the programme | 11,160,000 | 3,362,368,903 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 43,104,480 B shares of DKK 0.10 as treasury shares, corresponding to
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 24 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 25,919,179 B shares at an average share price of DKK 276.33 per B share equal to a transaction value of DKK 7,162,368,893.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 44 / 2026
Attachments
